Sinonasal carcinoma constitutes a rare subset of head and neck tumors. The majority of patients are diagnosed at a locally advanced stage, and the prognosis following recurrence or metastasis is extremely poor. Pembrolizumab is a humanized monoclonal antibody that targets programmed death-1 (PD-1) and reactivates T-cel...
A comprehensive review of immunotherapy for NPC is provided, evaluating current progress an persistent challenges by drawing insights from both completed and ongoing clinical trials.
Merkel cell carcinoma (MCC) represents a rare but highly aggressive neuroendocrine skin cancer with limited systemic therapy options for patients who fail or are ineligible for immune checkpoint inhibitors (ICIs). Intratumoral (IT) immunotherapy has emerged as a promising strategy, leveraging the accessibility of tumor...
Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer associated with early metastasis and poor outcomes in the advanced stages. Immune checkpoint inhibitors (ICIs), particularly avelumab, represent the first-line therapy for metastatic MCC. However, effective treatment options after progression...
ABSTRACT Introduction Recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) remains a significant clinical challenge despite advances in chemoradiation, with approximately 30% of patients ultimately developing R/M disease. There is an ongoing unmet need for novel therapeutic approaches that improve outcomes in thi...
Abstract Despite implementation of surveillance in at-risk populations and the availability of potentially curative treatment such as resection or ablation, recurrence of hepatocellular carcinoma (HCC) remains a frequent clinical challenge driven by both occult residual disease and de novo carcinogenesis, and can have...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
